Bold Therapeutics Inc.


Suite 500 – 666 Burrard St

Vancouver BC V6C 2P6


Member Sector: Biopharmaceuticals

Bold Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies.

Bold Therapeutics’ lead asset, BOLD-100, is a novel Cancer Resistance Pathway (CRP) inhibitor for the treatment of gastric, pancreatic and other cancers in combination with existing anti-cancer therapies. BOLD-100 was previously granted an Orphan Drug Designation (ODD) in the treatment of pancreatic
cancer, and Bold Therapeutics expects to initiate various Phase 1/2 studies of BOLD-100 in early 2019.